836
Participants
Start Date
June 6, 2019
Primary Completion Date
June 8, 2021
Study Completion Date
December 18, 2024
ExPEC10V
Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.
ExPEC4V
Participants will receive a single IM injection of ExPEC4V on Day 1.
Prevnar 13
Participants will receive a single IM injection of Prevnar 13 on Day 1.
Placebo
Participants will receive single IM injection of matching placebo on Day 1.
Clinical Pharmacology Unit, Merksem
Anima, Alken
ATC Pharma, Liège
Synexus Clinical Research US Inc, Manhattan
Hosp Reina Sofia, Córdoba
Rochester Clinical Research, Inc, Rochester
Hosp. Univ. de La Princesa, Madrid
Hosp. Univ. La Paz, Madrid
Coastal Carolina Research Center, North Charleston
Optimal Research, Melbourne
Qps-Mra, Llc, Miami
Chu Rennes Hopital Pontchaillou, Rennes
Optimal Research, Huntsville
CHRU Tours Hopital Bretonneau, Tours
Hosp. Univ. Marques de Valdecilla, Santander
Hosp. Virgen Macarena, Seville
Synexus Clinical Research US Inc, Columbus
CHU Nantes, Nantes
Synexus Clinical Research US Inc, Akron
Synexus Clinical Research US Inc, Evansville
Synexus Clinical Research US Inc, Richfield
Optimal Research, Peoria
Johnson County Clin-Trials, Lenexa
CHU Lyon Sud, Pierre-Bénite
Hopital Cochin, Paris
APHP - Hopital Bichat - Claude Bernard, Paris
EB Flevo Research, Almere Stad
PRA Health Sciences, Groningen
Hosp. Del Mar, Barcelona
Janssen Research & Development, LLC
INDUSTRY